- Home
- GRF vs KZR Comparison
GRF vs KZR Comparison
Compare GRF & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GRF | KZR |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9M | 44.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GRF | KZR |
|---|---|---|
| Price | $10.82 | $6.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.0K | ★ 42.2K |
| Earning Date | 01-01-0001 | 03-24-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.15 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.93 | $3.53 |
| 52 Week High | $10.19 | $6.57 |
Technical Indicators
Market Signals| Indicator | GRF | KZR |
|---|---|---|
| Relative Strength Index (RSI) | 48.65 | 58.20 |
| Support Level | $10.75 | $6.10 |
| Resistance Level | $11.09 | $6.40 |
| Average True Range (ATR) | 0.16 | 0.14 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 45.60 | 72.97 |
Price Performance
Historical ComparisonAbout GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.